A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJoerg Hasford, Hassan Ansari, Markus Pfirrmann et al.|JNCI Journal of the National Cancer Institute|1998Cited by 820
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Rüdiger Hehlmann, Michele Baccarani et al.|Blood|2011Cited by 497
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Rüdiger Hehlmann, Philipp Erben et al.|Leukemia|2012Cited by 417
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaRüdiger Hehlmann, Susanne Saußele, Michael Lauseker et al.|Journal of Clinical Oncology|2011Cited by 323